Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - hydrocortisone, quantity: 10 mg/ml; ciprofloxacin, quantity: 2 mg/ml - ear drops, suspension - excipient ingredients: polysorbate 20; sodium acetate; glacial acetic acid; benzyl alcohol; hydrogenated soy phosphatidylcholine; sodium chloride; polyvinyl alcohol; purified water - for the treatment of acute bacterial otitis externa, caused by organisms susceptible to ciprofloxacin (see pharmacology), in adults and children aged 2 years and older.

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - dexamethasone, quantity: 0.5 mg/ml; framycetin sulfate, quantity: 5 mg/ml; gramicidin, quantity: 0.05 mg/ml - ear drops - excipient ingredients: phenethyl alcohol; polysorbate 80; citric acid monohydrate; sodium citrate dihydrate; lithium chloride; purified water; industrial methylated spirit; sodium hydroxide; hydrochloric acid - indications as at 22 march 1993: inflammatory and allergic conditions of the ear, e.g. otitis externa. eczema of the auditory meatus is often present and causes inflammation, exudation and pruritus, which are all rapidly relieved by dexamethasone. infection,often secondary to scratching, is generally due to staphylococci, e. coli, pseudomonas and proteus spp. which respond rapidly to framycetin.

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - dexamethasone, quantity: 0.5 mg/ml; framycetin sulfate, quantity: 5 mg/ml; gramicidin, quantity: 0.05 mg/ml - ear drops - excipient ingredients: phenethyl alcohol; polysorbate 80; citric acid monohydrate; sodium citrate dihydrate; lithium chloride; purified water; industrial methylated spirit; hydrochloric acid; sodium hydroxide - indications as at 5 october 2000: inflammatory and allergic conditions of the ear, e.g. otitis externa. eczema of the auditory meatus is often present and causes inflammation, exudation and pruritus, which are all rapidly relieved by dexamethasone. infection,often secondary to scratching, is generally due to staphylococci, e. coli, pseudomonas and proteus spp. which respond rapidly to framycetin.

Australia - English - Department of Health (Therapeutic Goods Administration)

amdipharm mercury australia pty ltd - flumetasone pivalate, quantity: 0.2 mg/ml; clioquinol, quantity: 10 mg/ml - ear drops - excipient ingredients: macrogol 300 - this product accepted for registration/listing as 'currently supplied' at the time of commencement of the act. new indications were approved as specified in the letter of 29 june 1992 from dr alex proudfoot. indicated for the treatment of eczema of the external auditory meatus in which secondary infection with micro-organisms sensitive to clioquinol has occurred. otitis externa. otomycosis.

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - ciprofloxacin hydrochloride, quantity: 3.5 mg/ml (equivalent: ciprofloxacin, qty 3 mg/ml) - ear drops, solution - excipient ingredients: purified water; sodium acetate; mannitol; hydrochloric acid; glacial acetic acid; benzalkonium chloride; disodium edetate; sodium hydroxide - treatment of chronic suppurative otitis media caused by organisms susceptible to ciprofloxacin in adults and children one month of age or older.

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - ciprofloxacin hydrochloride, quantity: 3.5 mg/ml (equivalent: ciprofloxacin, qty 3 mg/ml) - ear drops, solution - excipient ingredients: mannitol; purified water; benzalkonium chloride; sodium hydroxide; disodium edetate; sodium acetate; hydrochloric acid; glacial acetic acid - treatment of chronic suppurative otitis media caused by organisms susceptible to ciprofloxacin in adults and children one month of age or older.

Ireland - English - HPRA (Health Products Regulatory Authority)

glaxosmithkline (ireland) limited - polymyxin b sulfate neomycin sulfate hydrocortisone - ear drops suspension - 10000 iu/ml

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - nystatin, quantity: 90000 u/ml; triamcinolone acetonide, quantity: 0.9 mg/ml; gramicidin, quantity: 0.225 mg/ml; neomycin sulfate (equivalent: neomycin, qty 2.25 mg/ml) - ear drops, solution - excipient ingredients: polyethylene; liquid paraffin - treatment of otitis externa (acute and chronic) when a topical corticosteroid is required and active infections with susceptible organisms are either present or likely to supervene

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - nystatin, quantity: 90000 u/ml; triamcinolone acetonide, quantity: 0.9 mg/ml; gramicidin, quantity: 0.225 mg/ml; neomycin sulfate (equivalent: neomycin, qty 2.25 mg/ml) - ear drops, solution - excipient ingredients: polyethylene; liquid paraffin - otocomb otic is indicated for the treatment of otitis externa (acute and chronic) when a topical corticosteroid is required and active infections with susceptible organisms are either present or likely to supervene.

Malta - English - Medicines Authority

the wellcome foundation 980 great west road, brentford, middlesex, tw8 9gs, united kingdom - polymyxin b, sulfate, hydrocortisone, neomycin sulfate - ear drops, suspension - polymyxin b sulfate 10000 u/ml hydrocortisone 1 % (w/v) neomycin sulfate 3400 u/ml - otologicals